Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „least“
Suchtreffer
Begriffe & Kennungen
Baiama · 4.8 · The most frequently observed adverse reactions (in at least 5% of patients treated with aflibercept) were conj
Eintrag öffnenBaraclude · 4.8 · Adverse reactions considered at least possibly related to treatment with entecavir are listed by body system o
Eintrag öffnenBaraclude · 4.8 · Adverse reactions considered at least possibly related to treatment with entecavir are listed by body system o
Eintrag öffnenBesponsa · 4.8 · In Cohort 3 of the Phase 2 ITCC-059 trial thirty-five VHR first relapsed BCP-ALL patients had at least 1 adver
Eintrag öffnenBetmiga · 4.8 · The safety of Betmiga was evaluated in 8 433 adult patients with OAB, of which 5 648 received at least one dos
Eintrag öffnenBexsero · 4.8 · Adverse reactions (following primary immunisation or booster dose) considered as being at least possibly relat
Eintrag öffnenBiktarvy · 4.5 · For pregnant patients: Biktarvy should be administered at least 2 hours before or 6 hours after taking oral me
Eintrag öffnenBortezomib Accord · 4.8 · 18 BzR-CAP arm that were considered by investigators to have at least a possible or probable causal relationsh
Eintrag öffnenBortezomib Accord · 4.8 · 51 BzR-CAP arm that were considered by investigators to have at least a possible or probable causal relationsh
Eintrag öffnenBosulif · 4.8 · A total of 1 372 leukaemia adult patients received at least 1 dose of single-agent bosutinib. The median durat
Eintrag öffnenBosulif · 4.8 · A total of 55 paediatric patients ≥ 1 year of age received at least 1 dose of bosutinib in the Phase I/II, mul
Eintrag öffnenBosulif · 4.8 · At least 1 adverse reaction of any toxicity grade was reported for 1,349 (98.3%) patients. The most frequent a
Eintrag öffnenBosulif · 4.8 · At least 1 adverse reaction of any toxicity grade was reported for 54 (98.2%) paediatric patients. The most fr
Eintrag öffnenCabometyx · 4.8 · The most frequent adverse reactions of any grade (experienced by at least 25% of patients) in the RCC, HCC, DT
Eintrag öffnenCasgevy · 4.5 · Discontinue the use of voxelotor and crizanlizumab at least 8 weeks prior to start of mobilisation and conditi
Eintrag öffnenCasgevy · 4.5 · Iron chelators must be discontinued at least 7 days prior to initiation of myeloablative conditioning, due to
Eintrag öffnenCasgevy · 4.5 · Use of hydroxyurea/hydroxycarbamide must be discontinued at least 8 weeks prior to start of mobilisation and c
Eintrag öffnenCatiolanze · 4.8 · Long term safety data are available from a Phase 3 study in which 118 patients received Catiolanze at least fo
Eintrag öffnenCayston · 4.8 · The adverse reactions considered at least possibly related to treatment from clinical study and post- marketin
Eintrag öffnenCeplene · 4.8 · Adverse reactions were reported to be at least possibly related to IL-2 and Ceplene treatment in almost all pa
Eintrag öffnen